MOUNTAIN VIEW, Calif.,
March 24, 2015 /PRNewswire/
-- As indicated in a Form 8-K filed with the SEC on
March 20, 2015, Omnicell, Inc.
received a written notification from the NASDAQ OMX Group, Inc. on
March 18, 2015, indicating that the
Company was not in compliance with Nasdaq Listing Rule 5250(c)(1)
for continued listing, due to the delay in filing its Annual Report
on Form 10-K for the period ended December 31, 2014 beyond the
extended filing due date of March 17, 2015. Under the Nasdaq
continued listing rules, Omnicell has 60 calendar days to either
file the Form 10-K or submit a plan to regain compliance. If the
plan is accepted and Omnicell has not otherwise regained compliance
by filing the Form 10-K, Nasdaq can grant an exception of up to 180
calendar days from the Form 10-K's due date, or until September 14,
2015, to regain compliance.
The Notice has no immediate effect on the listing of Omnicell's
common stock on Nasdaq. Omnicell is currently working diligently to
complete its internal investigation previously disclosed in the
Form 12b-25 filed on March 2, 2015
and Form 8-K filed on March 17, 2015.
Once the internal investigation process is complete, Omnicell plans
to file the Form 10-K as soon as practicable thereafter.
About Omnicell
Since 1992, Omnicell (NASDAQ: OMCL) has been creating new
efficiencies to improve patient care, anywhere it is delivered.
Omnicell is a leading supplier of comprehensive automation and
business analytics software for patient-centric medication and
supply management across the entire healthcare continuum— from the
acute care hospital setting to post-acute skilled nursing and
long-term care facilities to the home.
More than 3,000 customers worldwide have utilized Omnicell
Automation and Analytics solutions to increase operational
efficiency, reduce errors, deliver actionable intelligence and
improve patient safety. Omnicell Medication Adherence solutions,
including its MTS Medication Technologies brand, provide innovative
medication adherence packaging solutions to help reduce costly
hospital readmissions. In addition, these solutions enable
approximately 6,000 institutional and retail pharmacies worldwide
to maintain high accuracy and quality standards in medication
dispensing and administration while optimizing productivity and
controlling costs.
For more information about Omnicell, Inc. please visit
www.omnicell.com.
OMCL-E
Logo -
http://photos.prnewswire.com/prnh/20120731/SF48971LOGO-a
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/omnicell-inc-receives-expected-nasdaq-notification-of-noncompliance-300055408.html
SOURCE Omnicell, Inc.